PSMA-Targeted PET Imaging
Doctors use imaging tests to monitor prostate cancer and see if it has spread to other parts of the body. Magnetic resonance imaging (MRI) and bone scans are standard tests used to evaluate prostate cancer. However, these tests may not be useful if it is unclear where prostate cancer has potentially spread.1
In these cases, a new imaging test called prostate-specific membrane antigen (PSMA)-targeted positron emission tomography (PET) imaging can be used. Two drugs are currently approved by the U.S. Food and Drug Administration (FDA) for PSMA-targeted PET imaging.
Your doctor can help you decide whether this new imaging method is right for you.
How do PSMA-targeted PET imaging drugs work?
PSMA-targeted PET imaging drugs help doctors monitor prostate cancer. Doctors use them in certain cases to see whether the cancer has spread to other parts of the body or if the cancer has returned following previous treatment.2,3
Doctors give these drugs by intravenous (into the vein) injection. The drugs are designed to bind a protein called PSMA. Prostate cancer cells often have much higher levels of PSMA than noncancerous cells. This means that PSMA-targeted drugs will bind to and help identify prostate cancer cells.2,3
PSMA-targeted PET imaging drugs are considered radioactive. These drugs can be detected by PET imaging. This allows doctors to see PSMA-positive cancers in imaging tests.2,3
PSMA-targeted PET imaging can help doctors determine if prostate cancer has moved to other areas of the body or has returned following previous treatment. Doctors then use this information to decide on the best possible treatment.2,3
What the FDA has approved
As of early 2021, 2 PSMA-targeted PET imaging drugs for men with prostate cancer are approved by the FDA. These include:4,5
- Gallium 68 PSMA-11 (Ga 68 PSMA-11)
- Piflufolastat F 18 (PylarifyⓇ)
Ga 68 PSMA-11 and Pylarify are meant for men whose prostate cancer:4,5
- May have spread to another part of the body and is potentially curable with surgery or other therapies, or
- Seems to have returned based on high prostate-specific antigen (PSA) levels
Clinical trials confirmed that Ga 68 PSMA-11 and Pylarify can identify where prostate cancer has spread. The drugs can also detect sites where prostate cancer has returned. This provides doctors with important information for deciding on treatment.4,5
What are the possible side effects?
The most common side effects of Ga 68 PSMA-11 include:2,4
The most common side effects of Pylarify include:3,5
- Altered taste
These are not all the possible side effects of PSMA-targeted PET imaging drugs. Talk to your doctor about what to expect or if you experience any changes that concern you during treatment with PSMA-targeted PET imaging drugs.
Things to know
Your doctor will perform PET imaging about 1 to 2 hours after giving you the imaging agent. They will tell you to drink water before and after injection. This helps make sure you stay hydrated and can urinate before PET imaging. This can reduce exposure to radiation.4,5
There is a potential risk for misdiagnosis from PSMA-targeted PET imaging drugs. This can happen if the drugs bind other types of cancer or non-cancerous cells. Like any radioactive drug, there are also radiation risks. Receiving these radioactive drugs contributes to lifetime radiation exposure.2,3
Some machines do a PET scan at the same time as an MRI or other imaging tests. This can give better detail about areas that show up on the PET scan. PSMA-targeted PET imaging drugs are not yet available in all imaging centers. Talk to your doctor to find a place that uses these new methods.1
Before beginning treatment for prostate cancer, tell your doctor about all your health conditions and any other drugs, vitamins, or supplements you are taking. This includes over-the-counter drugs.